The Prognostic Value of Eight Immunohistochemical Markers Expressed in the Tumor Microenvironment and on Hodgkin Reed-Sternberg Cells in Pediatric Patients With Classical Hodgkin Lymphoma.
children
classical Hodgkin lymphoma
immunohistochemical markers
pediatric
prognosis
prognostic markers
prognostic value
Journal
Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
04
2022
accepted:
17
06
2022
entrez:
29
8
2022
pubmed:
30
8
2022
medline:
31
8
2022
Statut:
epublish
Résumé
Immunohistochemical markers are associated with treatment outcome in adults with classical Hodgkin Lymphoma (cHL). Studies in children are scarce and inconsistent. We investigated in 67 children with cHL, whether the expression of CD15, CD30, PAX5, PD-1, PD-L1, CD68, CD163 and TARC at diagnosis is associated with disease free survival (DFS) and with interim remission status. Low CD15 and low TARC expression were associated with relapsed disease. Low expression of PD-L1 was associated with complete remission at interim PET-scan. Our data suggest a difference between pediatric and adult cHL. This underlines the importance of future research into specific prognostic factors in pediatric cHL, indispensable for improvement of treatment in this population.
Identifiants
pubmed: 36032657
doi: 10.3389/pore.2022.1610482
pii: 1610482
pmc: PMC9402887
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1610482Informations de copyright
Copyright © 2022 Zijtregtop, Tromp, Dandis, Zwaan, Lam, Meyer-Wentrup and Beishuizen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Br J Haematol. 2020 Jul;190(1):40-44
pubmed: 32106342
Pediatr Blood Cancer. 2004 Jul;43(1):8-16
pubmed: 15170884
Blood. 2017 Nov 30;130(22):2420-2430
pubmed: 28893733
J Clin Oncol. 2019 Aug 10;37(23):1997-2007
pubmed: 31112476
Mediterr J Hematol Infect Dis. 2014 Jul 05;6(1):e2014053
pubmed: 25045461
Lancet Haematol. 2018 Oct;5(10):e450-e461
pubmed: 30290902
CA Cancer J Clin. 2018 Mar;68(2):116-132
pubmed: 29194581
Blood. 2008 Aug 15;112(4):1424-33
pubmed: 18541724
Eur J Cancer. 2013 Oct;49(15):3255-61
pubmed: 23791542
Curr Hematol Malig Rep. 2020 Aug;15(4):372-381
pubmed: 32394185
J Clin Oncol. 2016 Aug 10;34(23):2690-7
pubmed: 27069084
J Clin Oncol. 2005 Oct 20;23(30):7604-13
pubmed: 16186595
N Engl J Med. 2010 Mar 11;362(10):875-85
pubmed: 20220182
Cancer Immunol Immunother. 2021 Jun;70(6):1519-1526
pubmed: 33184699
Am J Surg Pathol. 2001 Jul;25(7):925-9
pubmed: 11420464
J Clin Oncol. 2021 Jul 10;39(20):2276-2283
pubmed: 33826362
Lancet Oncol. 2022 Jan;23(1):125-137
pubmed: 34895479
Am J Pathol. 1997 Oct;151(4):1123-30
pubmed: 9327746
Eur J Haematol. 2012 Apr;88(4):292-305
pubmed: 22044760
Turk Patoloji Derg. 2021;37(2):130-138
pubmed: 33085074
Blood. 2010 Oct 28;116(17):3268-77
pubmed: 20628145
Blood. 2012 Oct 18;120(16):3280-7
pubmed: 22948049
Eur J Immunol. 2006 Jul;36(7):1882-91
pubmed: 16810739
Haematologica. 2001 Nov;86(11):1227-8
pubmed: 11694413
J Clin Oncol. 2014 Nov 10;32(32):3651-8
pubmed: 25311218
Blood. 2019 Apr 18;133(16):1762-1765
pubmed: 30723079
J Pathol. 2010 Jul;221(3):248-63
pubmed: 20527019
Cancer Rep (Hoboken). 2021 Apr;4(2):e1311
pubmed: 33103852
Appl Immunohistochem Mol Morphol. 2016 Jul;24(6):383-91
pubmed: 26067141
Blood Adv. 2017 Aug 08;1(18):1427-1439
pubmed: 29296784
Clin Cancer Res. 2012 Jul 15;18(14):3762-71
pubmed: 22645050
Int J Cancer. 2012 Sep 1;131(5):1142-52
pubmed: 22025264
BMC Med. 2016 Oct 17;14(1):159
pubmed: 27745550
Pediatr Blood Cancer. 2008 Feb;50(2):280-3
pubmed: 17417795
Cancers (Basel). 2021 Feb 20;13(4):
pubmed: 33672548